EMPagliflozin After Aortic Valve Replacement
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT06171802
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 206 participants
- Registry
-
NCT06171802
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark
- Registry status
- Completed
Technical summary
Registry record NCT06171802. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-14 (actual); primary completion 2026-05-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EMPagliflozin After Aortic Valve Replacement
- Acronym
- EMPAVR
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
Record details
- Record id
cardio:ct-nct06171802- Content hash
d050e93b3e60ae9901e685d2fd30de24f82c3516758a2e6ffc49fd678e5497e6